Doctors diagnose as many as 60,000 new cases of Parkinson’s disease (PD) every year in the United States. Yet diagnosing PD with certainty can take years — long after early signs and symptoms have appeared.

The Israeli startup BioShai has a game-changing product on the horizon: PDx, the world’s first simple blood test for the early diagnosis of PD.

The test results can be combined with clinical data, providing a more accurate diagnosis to help physicians decide on the best course of treatment at a much earlier stage.

More than 10 million people worldwide are living with this chronic and progressive movement disorder caused by the malfunction and death of neurons that produce dopamine, a chemical that coordinates the brain’s control of movement and coordination.

“Having a diagnosis at an earlier stage can lead to a more precise treatment and a higher quality of life for the patient,” says BioShai CEO Jennifer Yarden, who has a PhD in medical science and formerly was responsible for clinical and commercial development of diagnostic assays and kits at Glycominds. Yarden is also CEO and cofounder of Curewize Health.

“Offering a simple and inexpensive test for the diagnosis of Parkinson’s is considered essential for the development of neuroprotective therapy,” she explains, “because by the time a patient has the many movement symptoms associated with Parkinson’s, a majority of the dopamine-producing neurons are lost or become impaired by the disease.”